Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bioage Labs Inc (BIOA)

Bioage Labs Inc (BIOA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 716,737
  • Shares Outstanding, K 44,380
  • Annual Sales, $ 8,995 K
  • Annual Income, $ -71,110 K
  • EBIT $ -90 M
  • EBITDA $ -90 M
  • 60-Month Beta 1.22
  • Price/Sales 80.18
  • Price/Cash Flow N/A
  • Price/Book 2.14

Options Overview Details

View History
  • Implied Volatility 120.58% (-33.87%)
  • Historical Volatility 84.20%
  • IV Percentile 30%
  • IV Rank 9.06%
  • IV High 826.12% on 04/04/25
  • IV Low 50.29% on 09/17/25
  • Expected Move (DTE 18) 5.06 (31.95%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 83
  • Put/Call OI Ratio 2.83
  • Today's Open Interest 1,513
  • Open Int (30-Day) 2,304
  • Expected Range 10.77 to 20.89

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.71
  • Number of Estimates 3
  • High Estimate -0.66
  • Low Estimate -0.74
  • Prior Year -0.36
  • Growth Rate Est. (year over year) -97.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.47 +2.33%
on 03/25/26
22.02 -28.11%
on 03/02/26
-6.44 (-28.92%)
since 02/27/26
3-Month
11.87 +33.40%
on 01/05/26
24.00 -34.04%
on 01/15/26
+1.95 (+14.05%)
since 12/26/25
52-Week
2.88 +449.65%
on 04/09/25
24.00 -34.04%
on 01/15/26
+12.01 (+314.40%)
since 03/28/25

Most Recent Stories

More News
Bioage Labs Faces Widening Losses as Analysts Watch Clinical Pipeline Ahead of Earnings

Barchart Research What to Expect from BIOA Earnings BIOA Generated March 25, 2026 Current Price $16.41 EPS Estimate $-0.74 Consensus Rating Moderate Buy Average Move 4.45% Bioage Labs Faces Widening Losses...

BIOA : 15.83 (-1.98%)
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025

Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor, demonstrating potential best-in-class reductions in inflammatory...

BIOA : 15.83 (-1.98%)
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for...

BIOA : 15.83 (-1.98%)
BioAge Announces Pricing of Upsized $115.0 Million Public Offering

EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates...

BIOA : 15.83 (-1.98%)
BioAge Announces Proposed Public Offering

EMERYVILLE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates...

BIOA : 15.83 (-1.98%)
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026

BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies Growing preclinical and...

BIOA : 15.83 (-1.98%)
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk

First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers BGE-102 achieved 86% reduction in...

BIOA : 15.83 (-1.98%)
Beyond Weight Loss: The "Cellular Reset" That Could Create the Next Biotech Supercycle

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The longevity economy is entering a massive repricing event as researchers confirm that metabolic dysfunction...

LGVN : 0.9304 (+1.13%)
AVAI : 0.2900 (-16.09%)
BIOA : 15.83 (-1.98%)
GAA : 32.98 (-0.43%)
DNLI : 18.08 (-0.44%)
MAPT : 0.0003 (+50.00%)
KLTO : 0.5242 (+0.81%)
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing Strong target engagement: BGE-102 achieved 90-98% suppression of IL-1β,...

BIOA : 15.83 (-1.98%)
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference

EMERYVILLE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for...

BIOA : 15.83 (-1.98%)

Business Summary

BioAge Labs Inc. is a clinical-stage biopharmaceutical company. It involved in developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of aging. BioAge Labs Inc. is based in RICHMOND, Calif.

See More

Key Turning Points

3rd Resistance Point 17.12
2nd Resistance Point 16.78
1st Resistance Point 16.31
Last Price 15.83
1st Support Level 15.50
2nd Support Level 15.16
3rd Support Level 14.69

See More

52-Week High 24.00
Fibonacci 61.8% 15.93
Last Price 15.83
Fibonacci 50% 13.44
Fibonacci 38.2% 10.95
52-Week Low 2.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.